Reading Time: 2 minutes
Labcorp Holdings (LH) appeals to me as a defensive shovel seller in the biotech revolution. The company conducts over 750 million tests annually and supported over 85% of the newly FDA-approved drugs and therapies in 2025. At the same time, precision medicine is likely to increase the demand for genome, biomarker, and companion diagnostic tests further. I find oncology particularly exciting, where Labcorp offers more than 450 tests, and CEO Adam Schechter anticipates market growth two to three times higher than the overall laboratory market. AI...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
